中国医药科学2025，Vol.15Issue(5)：25-28,4.DOI:10.20116/j.issn2095-0616.2025.05.06
肝细胞癌免疫治疗研究进展
Research progress of immunotherapy for hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma(HCC)is a malignant tumor with occult onset,poor prognosis and high morbidity and mortality.In the past,molecular targeted drugs such as sorafenib have been the main means of systematic treatment of HCC,but they can only provide limited survival benefits.In recent years,with the development of cancer immunotherapy,immunotherapy has provided a new treatment for HCC.The combination of atilizumab and bevacizumab showed a significant improvement in survival,and the combination of immune checkpoint inhibitor and double immune checkpoints also achieved satisfactory results.In addition,chimeric antigen receptor T cells,oncolytic virus and tumor vaccine are also in the early clinical trial stage for the treatment of HCC.This paper briefly reviews and summarizes the immunotherapy for HCC that has been and is being developed at present.关键词
肝细胞癌/免疫检查点抑制剂/CAR-T疗法/溶瘤病毒/肿瘤疫苗Key words
Hepatocellular carcinoma/Immune checkpoint inhibitor/CAR-T therapy/Oncolytic virus/Tumor vaccine分类
医药卫生引用本文复制引用
孙照兴,李一权,汪伟,李文杰..肝细胞癌免疫治疗研究进展[J].中国医药科学,2025,15(5):25-28,4.基金项目
吉林省教育厅科学技术研究项目(JJKH20220873KJ). （JJKH20220873KJ）
